cefadroxil 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antibiotics, cefalosporanic acid derivatives 526 50370-12-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • cefadroxil
  • cefadrox
  • cephadroxil
  • cefadroxil hemihydrate
Long-acting, broad-spectrum, water-soluble, CEPHALEXIN derivative.
  • Molecular weight: 363.39
  • Formula: C16H17N3O5S
  • CLOGP: -2.51
  • LIPINSKI: 0
  • HAC: 8
  • HDO: 4
  • TPSA: 132.96
  • ALOGS: -2.96
  • ROTB: 4
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
2 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 4 Bocci G, Oprea TI, Benet LZ
S (Water solubility) 1 mg/mL Bocci G, Oprea TI, Benet LZ
EoM (Fraction excreted unchanged in urine) 93 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 78.62 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 95 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 0.23 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 2.50 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.39 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.10 hours Lombardo F, Berellini G, Obach RS

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 -1.701 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.417 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 0.532 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 1.368 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 79.360 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 55.620 % High 1
herg hERG pIC50 4.496 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.698 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.963 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 59.830 % High 1
kinase-safety-class ACVR2A,ACVR2B,ACVRL1,AURKA,AXL,BRAF,BTK,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,GRK2,GRK3,GSK3B,ITK,JAK2,JAK3,KDR,MAP2K6,MAP3K14,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PIK3CA,PIK3CB,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TGFBR1,TTK 42
kinase-selectivity-class ACVR2B,AXL,BRAF,CDK4,CDK9,DYRK1B,EIF2AK3,EPHB4,GRK2,JAK2,MAP2K6,MAP3K14,MAPK7,PRKDC,STK33,SYK,TEK,TGFBR1,TTK 19
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 0.597 Moderate 0.70
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 0.593 High 1
mh-clint Mouse hepatocyte intrinsic clearance 3.597 High 1
mppb Mouse plasma protein binding (% unbound) 81.290 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 1.089 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 62.450 % High 1
rat-kpuu-brain Rat brain Kpuu 0.007 % Moderate 0.70
rh-clint Rat hepatocyte intrinsic clearance 1.730 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 87.140 % High 1
rppb Rat plasma protein binding (% unbound) 58.440 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 899.498 uM High 1

Approvals:

DateAgencyCompanyOrphan
Feb. 17, 1978 FDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nasal oedema 923.52 30.16 181 5497 6403 90616366
Respiratory tract infection 502.25 30.16 174 5504 58904 90563865
Oedema 394.85 30.16 209 5469 200086 90422683
Asthma 352.41 30.16 207 5471 241953 90380816
Drug hypersensitivity 343.70 30.16 260 5418 463349 90159420
Cross sensitivity reaction 342.46 30.16 69 5609 2788 90619981
Chest pain 285.51 30.16 201 5477 319444 90303325
Wheezing 250.94 30.16 166 5512 237914 90384855
Cough 231.58 30.16 188 5490 368774 90253995
Type IV hypersensitivity reaction 226.88 30.16 52 5626 3874 90618895
Pneumonia 189.43 30.16 215 5463 637844 89984925
Malaise 176.42 30.16 199 5479 585787 90036982
Pain 171.08 30.16 256 5422 996085 89626684
Vomiting 150.11 30.16 213 5465 788080 89834689
Dyspnoea 117.21 30.16 202 5476 880753 89742016
Rash maculo-papular 83.78 30.16 44 5634 40889 90581880
Metastatic malignant melanoma 65.05 30.16 16 5662 1608 90621161
Urticaria thermal 64.59 30.16 13 5665 520 90622249
Administration site erythema 52.28 30.16 12 5666 897 90621872
Skin plaque 36.53 30.16 16 5662 9959 90612810
Pigmentation disorder 33.56 30.16 13 5665 5936 90616833
Iodine allergy 31.83 30.16 8 5670 878 90621891
Vitamin B12 deficiency 30.67 30.16 13 5665 7473 90615296
Scratch 30.32 30.16 14 5664 9852 90612917

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Cross sensitivity reaction 172.23 27.38 30 888 1645 42618772
Pneumonia haemophilus 38.90 27.38 8 910 1056 42619361
Clostridium difficile colitis 27.73 27.38 12 906 21240 42599177
Asthma 27.64 27.38 17 901 62297 42558120

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nasal oedema 938.59 24.59 181 5948 6658 110576512
Respiratory tract infection 486.36 24.59 173 5956 71444 110511726
Cross sensitivity reaction 473.44 24.59 99 6030 5468 110577702
Oedema 424.14 24.59 214 5915 209762 110373408
Asthma 411.03 24.59 222 5907 250069 110333101
Drug hypersensitivity 348.69 24.59 248 5881 453842 110129328
Chest pain 273.33 24.59 199 5930 376176 110206994
Wheezing 256.36 24.59 165 5964 255065 110328105
Type IV hypersensitivity reaction 231.36 24.59 56 6073 5977 110577193
Cough 216.75 24.59 189 5940 461452 110121718
Pain 197.48 24.59 252 5877 954703 109628467
Pneumonia 180.49 24.59 231 5898 876483 109706687
Malaise 177.36 24.59 201 5928 671618 109911552
Vomiting 141.98 24.59 210 5919 910465 109672705
Dyspnoea 100.51 24.59 201 5928 1106671 109476499
Rash maculo-papular 66.91 24.59 45 6084 74177 110508993
Urticaria thermal 66.22 24.59 13 6116 518 110582652
Administration site erythema 62.45 24.59 12 6117 427 110582743
Drug reaction with eosinophilia and systemic symptoms 35.03 24.59 32 6097 82063 110501107
Pigmentation disorder 32.51 24.59 13 6116 7298 110575872
Skin plaque 31.67 24.59 15 6114 12630 110570540
Vitamin B12 deficiency 28.52 24.59 13 6116 10042 110573128
Scratch 28.29 24.59 14 6115 12965 110570205
Erythema 27.44 24.59 54 6075 291393 110291777
Off label use 26.04 24.59 27 6102 1500158 109083012
Veillonella infection 25.02 24.59 4 6125 47 110583123

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC J01DB05 ANTIINFECTIVES FOR SYSTEMIC USE
ANTIBACTERIALS FOR SYSTEMIC USE
OTHER BETA-LACTAM ANTIBACTERIALS
First-generation cephalosporins
CHEBI has role CHEBI:33231 antitubercular agent
CHEBI has role CHEBI:33282 antibacterial agent
CHEBI has role CHEBI:35441 antiinfective agent
CHEBI has role CHEBI:36047 antibacterial drug
MeSH PA D000890 Anti-Infective Agents
MeSH PA D000900 Anti-Bacterial Agents

Related Drugs by ATC class:

J01DB First-generation cephalosporins 11 drugs
cefacetrilecefalexincefaloridinecefalotincefapirincefatrizinecefazedonecefazolincefradinecefroxadineceftezole

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Infection of skin AND/OR subcutaneous tissue indication 19824006
Streptococcal tonsillitis indication 41582007
Klebsiella cystitis indication 60867007
Urinary tract infectious disease indication 68566005
Tonsillitis indication 90176007 DOID:10456
Escherichia coli urinary tract infection indication 301011002
Proteus urinary tract infection indication 301012009
Streptococcus pyogenes infection indication 302809008
Infection due to Staphylococcus aureus indication 406602003
Prevention of Bacterial Endocarditis off-label use
Impaired renal function disorder contraindication 197663003
Pseudomembranous enterocolitis contraindication 397683000




🐶 Veterinary Drug Use

SpeciesUseRelation
Cats Skin and soft tissue infections caused by susceptible strains of Staphylococcus aureus Indication
Cats Genitourinary tract infections caused by Escherichia coli Indication
Cats Genitourinary tract infections caused by Proteus species Indication
Cats Genitourinary tract infections caused by Staphylococcus aureus Indication
Cats Skin and soft tissue infections caused by Pasteurella multocida Indication
Cats Skin and soft tissue infections caused by Staphylococcus epidermidis Indication
Cats Skin and soft tissue infections caused by Streptococcus species Indication
Dogs Skin and soft tissue infections caused by Staphylococcus aureus Indication
Dogs Genitourinary tract infections caused by Escherichia coli Indication
Dogs Genitourinary tract infections caused by Proteus species Indication
Dogs Genitourinary tract infections caused by Staphylococcus aureus Indication

🐶 Veterinary products

ProductApplicantIngredients
Cefa-Tabs HQ Specialty Pharma Corp. 1
Cefa-Drops HQ Specialty Pharma Corp. 1

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 2.77 acidic
pKa2 9.72 acidic
pKa3 13.53 acidic
pKa4 7.63 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Solute carrier family 15 member 1 Transporter Ki 2.14 WOMBAT-PK
Bacterial penicillin-binding protein Enzyme INHIBITOR CHEMBL CHEMBL

External reference:

IDSource
4018151 VUID
N0000146488 NUI
D00257 KEGG_DRUG
66592-87-8 SECONDARY_CAS_RN
1297878 RXNORM
C0007538 UMLSCUI
CHEBI:3479 CHEBI
A1APP PDB_CHEM_ID
CHEMBL1644 ChEMBL_ID
DB01140 DRUGBANK_ID
D002434 MESH_DESCRIPTOR_UI
47965 PUBCHEM_CID
4831 IUPHAR_LIGAND_ID
119922-85-9 SECONDARY_CAS_RN
280111G160 UNII
d00080 MMSL
13414000 SNOMEDCT_US
372651006 SNOMEDCT_US
4018151 VANDF
004959 NDDF
280111G160 INXIGHT DRUGS

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0093-3196 CAPSULE 500 mg ORAL ANDA 22 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 0093-4059 TABLET 1000 mg ORAL ANDA 23 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 10544-135 CAPSULE 500 mg ORAL ANDA 19 sections
CEFADROXIL Human Prescription Drug Label 1 16590-043 CAPSULE 500 mg ORAL ANDA 23 sections
Cefadroxil Human Prescription Drug Label 1 16714-388 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil Human Prescription Drug Label 1 16714-389 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 21 sections
Cefadroxil Human Prescription Drug Label 1 16714-390 POWDER, FOR SUSPENSION 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 21695-427 CAPSULE 500 mg ORAL ANDA 22 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 33261-018 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 42254-146 CAPSULE 500 mg ORAL ANDA 19 sections
CEFADROXIL Human Prescription Drug Label 1 42549-504 CAPSULE 500 mg ORAL ANDA 23 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 43063-553 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 43063-595 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 43063-595 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 45865-503 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil Human Prescription Drug Label 1 50090-1915 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil Human Prescription Drug Label 1 50090-6050 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 52959-428 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 53002-2290 CAPSULE 500 mg ORAL ANDA 19 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 54868-3742 CAPSULE 500 mg ORAL ANDA 13 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 54868-5693 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 14 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 54868-5694 POWDER, FOR SUSPENSION 500 mg ORAL ANDA 14 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 55289-589 CAPSULE 500 mg ORAL ANDA 22 sections
Cefadroxil Human Prescription Drug Label 1 57237-096 CAPSULE 500 mg ORAL ANDA 21 sections
Cefadroxil Human Prescription Drug Label 1 57237-097 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 21 sections
Cefadroxil Human Prescription Drug Label 1 57237-098 POWDER, FOR SUSPENSION 500 mg ORAL ANDA 21 sections
Cefadroxil HUMAN PRESCRIPTION DRUG LABEL 1 63187-883 CAPSULE 500 mg ORAL ANDA 19 sections
CEFADROXIL HUMAN PRESCRIPTION DRUG LABEL 1 63304-972 POWDER, FOR SUSPENSION 125 mg ORAL ANDA 21 sections
CEFADROXIL HUMAN PRESCRIPTION DRUG LABEL 1 63304-973 POWDER, FOR SUSPENSION 250 mg ORAL ANDA 21 sections
CEFADROXIL HUMAN PRESCRIPTION DRUG LABEL 1 63304-974 POWDER, FOR SUSPENSION 500 mg ORAL ANDA 21 sections